Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
$8.48
+2.8%		$6.83
$2.62
▼
$8.61
$848.94M2.251.38 million shs1.04 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$24.30
+1.3%		$32.34
$23.84
▼
$50.79
$781.34M0.72944,821 shs852,658 shs
GLAS
Glass House Brands
$8.52
+0.3%		$10.34
$5.15
▼
$13.93
$796.36MN/A423,137 shs655,943 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$5.77
-3.8%		$6.67
$2.80
▼
$8.97
$208.06M0.6337,931 shs1.36 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
+2.79%+2.54%+34.18%+60.30%+190.41%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+1.25%-11.67%-31.70%-25.67%-37.95%
GLAS
Glass House Brands
+0.55%-17.15%-15.62%+851,699,900.00%+851,699,900.00%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-2.04%+0.87%+12.48%-34.06%-50.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
$8.48
+2.8%		$6.83
$2.62
▼
$8.61
$848.94M2.251.38 million shs1.04 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$24.30
+1.3%		$32.34
$23.84
▼
$50.79
$781.34M0.72944,821 shs852,658 shs
GLAS
Glass House Brands
$8.52
+0.3%		$10.34
$5.15
▼
$13.93
$796.36MN/A423,137 shs655,943 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$5.77
-3.8%		$6.67
$2.80
▼
$8.97
$208.06M0.6337,931 shs1.36 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
+2.79%+2.54%+34.18%+60.30%+190.41%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+1.25%-11.67%-31.70%-25.67%-37.95%
GLAS
Glass House Brands
+0.55%-17.15%-15.62%+851,699,900.00%+851,699,900.00%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-2.04%+0.87%+12.48%-34.06%-50.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3.00
Buy$15.0076.89% Upside
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.71
Moderate Buy$51.00109.88% Upside
GLAS
Glass House Brands
2.00
Hold$16.0087.86% Upside
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SBTX, COLL, ACHV, and GLAS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
GLAS
Glass House Brands
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/19/2026
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/19/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$56.00 ➝ $48.00
8/14/2026
GLAS
Glass House Brands
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$15.00
8/13/2026
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$13.00
8/12/2026
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$18.00
8/12/2026
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/12/2026
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00
8/11/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
8/7/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$45.00 ➝ $43.00
8/6/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$56.00 ➝ $46.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/A($0.14) per shareN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$780.57M1.01$15.38 per share1.58$9.58 per share2.54
GLAS
Glass House Brands
N/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$54.65M-$1.55N/AN/AN/AN/A-511.12%-82.35%11/5/2026 (Estimated)
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$62.87M$1.2419.604.30N/A5.93%91.43%15.57%11/5/2026 (Estimated)
GLAS
Glass House Brands
N/AN/AN/A42.59N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/AN/A-29.62%-28.20%N/A

Latest SBTX, COLL, ACHV, and GLAS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$0.1649-$0.80-$0.6351-$0.80N/AN/A
8/6/2026Q2 2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.72$1.92+$0.20-$0.46$199.63 million$199.88 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
GLAS
Glass House Brands
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
0.87
0.95
0.95
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.32
1.03
0.84
GLAS
Glass House Brands
N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Institutional Ownership

CompanyInstitutional Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
33.52%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
GLAS
Glass House Brands
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
1.80%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
1.85%
GLAS
Glass House Brands
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
20102.90 million101.05 millionOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.56 million31.95 millionOptionable
GLAS
Glass House Brands
N/A93.80 millionN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

Meet the Silverback, the Leader of the Troop
October 17, 2024  |  pbs.orgP
10 Fun Facts About Mountain Gorillas
September 18, 2024  |  nationalgeographic.comN
CapstanTx secures $165 million to deliver precise in vivo cell engineering
July 28, 2024  |  pharmaphorum.comP
ARS Pharmaceuticals Inc (SPRY)
May 11, 2023  |  uk.investing.comhttps://uk.investing.com/equities/silverback-therapeutics-inc
Wild Isles
March 12, 2023  |  wwf.org.ukW
A look back at RNA Therapeutics – day one
February 23, 2023  |  pharmaphorum.comP
SPRY ARS Pharmaceuticals, Inc.
January 24, 2023  |  seekingalpha.comhttps://seekingalpha.com/symbol/SPRY
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
November 22, 2022  |  247wallst.comhttps://247wallst.com/investing/2022/11/22/ars-pharma-ceo-richard-lowenthal-holds-8-silverback-stake-after-merger/
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
November 18, 2022  |  nasdaq.comhttps://www.nasdaq.com/articles/dr.-sarina-tanimoto-discloses-position-in-sbtx-silverback-therapeutics
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 10, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-announces-presentation-clinical-130000987.html?.tsrc=rss
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
November 8, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-closes-merger-silverback-210200048.html?.tsrc=rss
Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
October 28, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/silverback-fda-accepts-ars-pharm-s-nda-for-neffy-for-treatment-of-allergic-reactions-1031824142
FDA accepts ARS Pharma’s NDA for Neffy
October 24, 2022  |  thepharmaletter.comT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI
October 23, 2022  |  kentuckytoday.comK
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
October 21, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/silverback-therapeutics-inc-announces-fda-113100379.html?.tsrc=rss
Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?
October 19, 2022  |  aaii.comA
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN
October 12, 2022  |  bakersfield.comB
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
September 17, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/investigation-alert-halper-sadeh-llc-investigates-cvet-sbtx-irbt-1031746211
SBTX Silverback Therapeutics, Inc.
September 15, 2022  |  seekingalpha.comhttps://seekingalpha.com/symbol/SBTX/charting
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
September 6, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/shareholder-notice-halper-sadeh-llp-investigates-ftai-sbtx-cvet-gbt-1031726462

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
T-Mobile logo illuminated in pink with a cell tower, city skyline, and smartphone in the foreground.
Dodging Deutsche Telekom: T-Mobile's Strategic Win
By Jeffrey Neal Johnson | August 4, 2026
Copper pipes and sheet stacks in a warehouse open to electrical transmission towers and a power substation at sunset.
Copper Surges as Shifting Trade Policy and AI Demand Collide
By Chris Markoch | September 2, 2026
Achieve Life Sciences stock logo

Achieve Life Sciences NASDAQ:ACHV

$8.48 +0.23 (+2.79%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$8.40 -0.08 (-0.90%)
As of 09/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$24.30 +0.30 (+1.25%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$24.28 -0.02 (-0.06%)
As of 09/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Glass House Brands NYSE:GLAS

$8.52 +0.03 (+0.32%)
Closing price 09/2/2026 03:59 PM Eastern
Extended Trading
$8.58 +0.07 (+0.79%)
As of 09/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$5.77 -0.23 (-3.83%)
As of 09/1/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas